10 Majority of patients had CVD and were receiving SOC 6,7,a 97% were receiving glucose-lowering medications 6 Patient characteristics at baseline (N=9650) 6,7 Select history of CVD at baseline (N=9650) 6 Select history of medication use at baseline (N=9650) 6,10 a Standard care consisted of glucose-lowering and cardiovascular riskreducing therapies administered in accordance with local guidelines
In diagnostic laboratories, plasma/serum Lp(a) concentration is determined mainly by immunochemical methods, i.e., immunoturbidimetric or immunonephelometric, or various immuno-enzyme methods, including ELISA
Direct clinical trials on NAD+ plus GLP-1 combinations are limited, but preclinical research shows NAD+ enhances mitochondrial function and may support metabolic efficiency during caloric restriction
That is why, in AIM-based kidney care for CKD cats, glutathione and antioxidant balance should be considered together